<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00231439</url>
  </required_header>
  <id_info>
    <org_study_id>HUS1</org_study_id>
    <nct_id>NCT00231439</nct_id>
  </id_info>
  <brief_title>Post-Poliosyndrome Treated With Intravenous Immunoglobulin (IvIg)</brief_title>
  <official_title>Post-Polio Syndrome Treated With Intravenous Immunoglobulin (IvIg)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Haukeland University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Haukeland University Hospital</source>
  <brief_summary>
    <textblock>
      Inflammatory cytokines in the cerebrospinal fluid may contribute to the new muscle weakness,&#xD;
      fatigue and pain experienced by patients with post-polio syndrome. Intravenousimmunoglobulin&#xD;
      (IvIg) reduces this inflammation. The purpose of this study is to investigate the clinical&#xD;
      effect of IvIg in post-polio syndrome.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Post-polio syndrome (PPS) is characterised by new muscle weakness, pain, and fatigue several&#xD;
      years after the attack of acute polio. This leads to increased disability, and up to now only&#xD;
      supportive therapy is available.&#xD;
&#xD;
      Patients with PPS lose more motor neurons than expected and surviving neurons fail to&#xD;
      maintain neurogenic supply to enlarged motor units. New data report an increased level of&#xD;
      inflammatory cytokines in the cerebrospinal fluid (CSF). Immune modulating therapy like IvIg&#xD;
      could be an option and this pilot study is the first to investigate the clinical effect of&#xD;
      IvIg in PPS. In addition, levels of cytokines in CSF and serum before and after treatment&#xD;
      will be investigated.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2003</start_date>
  <completion_date>July 2004</completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pain after three months</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Fatigue after 3 months</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Muscle strength after 3 months</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pain, Fatigue, Muscle strength after 6 months. Changes in cytokine levels in CSF and serum</measure>
  </secondary_outcome>
  <enrollment>40</enrollment>
  <condition>Post-Polio Syndrome</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IvIg</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Post-polio syndrome diagnosed at Dept of Neurology, Haukeland University Hospital Walking&#xD;
        ability -&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Other autoimmune disorders Other ongoing autoimmune therapy Severe cardiopulmonary disease&#xD;
        IgA deficiency Previous treatment of IvIg Wheelchair dependence&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>75 Months</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Elisabeth Farbu, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Stavanger University Hospital, Stavanger, Norway</affiliation>
  </overall_official>
  <verification_date>July 2003</verification_date>
  <study_first_submitted>September 30, 2005</study_first_submitted>
  <study_first_submitted_qc>September 30, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 4, 2005</study_first_posted>
  <last_update_submitted>December 12, 2005</last_update_submitted>
  <last_update_submitted_qc>December 12, 2005</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 13, 2005</last_update_posted>
  <keyword>Post-polio syndrome</keyword>
  <keyword>IvIg</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Postpoliomyelitis Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

